Abstract 428P
Background
Bone marrow aspiration although being a common procedure is associated with significant pain and its reduction remains an unmet need. We evaluated the use of tramadol and eutectic mixture of local anaesthetics (prilocaine plus lignocaine) (EMLA) for reducing the severity of pain.
Methods
In this pilot study, we compared the addition of either Tramadol 50 mg per oral (Arm T) or EMLA local application (Arm E) or no added intervention (Arm L) in addition to local infiltration with lignocaine 2% before bone marrow aspiration in adults suspected / confirmed with malignancy. Both, tramadol and EMLA were administered one hour prior to the procedure. Primary end point was reduction in pain intensity with these interventions compared to local infiltration alone. Pain was assessed using numerical FACES pain scale ( 0-10), a visual analogue scale.Secondary end points were to see the effect on pre procedure apprehension and to find out other factors associated with increased pain associated with the procedure.
Results
A total of 225 patients were included in the study, 75 each in tramadol(T), EMLA(E) and only lignocaine local infiltration(L) arms respectively. The mean pain intensity on the visual scale was significantly lower in tramadol arm ( T,E,L - 3.3 , 4.5 , 4.7 respeactively)(p < 0.05). There was significant reduction in percentage of patients who experienced moderate / severe pain (4 or more) in tramadol arm (T,E,L - 47%,76%,84% respectively)(p < 0.05). Duration of procedure > 10 minutes and age > 50 were positively correlated with more pain. Leukemia patients had significantly more pain compared to lymphoma and other solid malignancies. Only 4 patients had sedation/dizziness in tramadol arm compared to 2 each in the other two arms. No significant effect on pre procedure apprehension was noted in any of the arms.
Conclusions
Tramadol appears to have a preventive effect on bone marrow aspiration associated pain and appears to be well tolerated. Whereas EMLA was not associated with such effect. Larger studies may be done to ascertain the same.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of medical oncology, Kidwai cancer institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract